SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline after the TDAPA transition has fueled a sharp selloff and concerns about pricing and revenue. Traders disagree over the impact: some see a lasting commercial headwind, while others argue DaVitas outlook is preliminary and may overstate the risk; frustration with managements communication is also prominent.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubos steep, low-volume decline and repeated new lows dominate the discussion, with many traders saying the selloff lacks a clear company-specific trigger. The community is looking to upcoming earnings and CEO Alisa Bowens strategic plan for clarity, while bears expect further downside and bulls argue for a turnaround or short-covering rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround 

Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Lyell Immunopharma Becomes Oversold (LYEL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.read more...

Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update

Lyell Immunopharma reports improved safety data for LYL273 in metastatic colorectal cancer and advances study to Phase 1/2 design.read more...

Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)

Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Tuesday

Lyell Immunopharma (NASDAQ:LYEL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-lyell-immunopharma-inc-stock...

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have iss...

Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Lyell Immunopharma from a "hold" rating to a "sell" rating in a research note on Saturday...

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Lyell Immunopharma Inc

WisdomTree, Lyell Immunobiopharma, DexCom Among Stocks Retailers Are Most Bullish In Friday's Premarket

Equity

Bearish Sentiment

WisdomTree, Inc. ($WT)Shares of WisdomTree, which offers a suite of exchange-traded and blockchain technology products, reported third-quarter earnings per share (EPS) of $0.18 compared to $0.10 per share a year-ago. This beat the consensus estimate of $0.18, according to Yahoo Finance.The shares climbed 4.50% to $10.85 as of 9:00 am ET, in premarket trading.WisdomTree’s assets under management at the end of the third quarter was $112.6 million, up from $109.7 million at the end of the second quarter. Operating revenue came in at $109.5 million compared to the $90.4 million reported for a year earlier. This was slightly shy of the consensus estimate of $110.07 million.<figure class="image"><a href="https://stocktwits.com/symbol/WT"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/wt_sentiment_34b5aa54e0.png" alt="wt-sentiment.png" width="637" height="135"></a><figcaption>WT sentiment and message volume October 25, 2024 premarket as of 9:00 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Retail sentiment was ‘extremely bullish’ (95/100) with message volume reducing from a day ago, yet at ‘high.’Lyell Immunopharma, Inc. ($LYEL)Small-cap Lyell Immunopharma, a clinical-stage CART T-cell therapy biotech, said late Thursday that it has entered into a definitive agreement to acquire privately-held&nbsp; ImmPACT Bio USA Inc for $30 million in cash and 37.5 million in stock.Through the acquisition, Lyell Immunopharma will acquire worldwide rights to ImmPACT’s pipeline. The company will prioritize the development of IMPT-314 for treating B-cell lymphoma, a type of blood cancer.ImmPACT shareholders are also eligible to receive contingent consideration of 12.5 million of Lyell Immunopharma stock as milestone-based payment as well as royalties on net sales.The deal has been vetted by the board of both companies and is expected to close in the fourth quarter.The stock gained 0.94% to $1.10 in premarket trading.DexCom, Inc. ($DXCM)Glucose monitoring device manufacturer Dexcom’s shares fell in premarket trading but retail sentiment remains ‘extremely bullish.'<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:632/145;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/dxcm_sentiment_f6ce5575e8.png" alt="dxcm-sentiment.png" width="632" height="145"></a><figcaption>&nbsp;DXCM sentiment and message volume October 25, 2024 premarket as of 9:00 am ET | Source:&nbsp;Stocktwits</figcaption></figure>DexCom’s third-quarter non-GAAP EPS came in at $0.45 compared to the consensus estimate of $0.43. Revenue rose 2% year-over-year from $975 million to $994.2 million. Analysts, on average, estimated a modest $990.44 million for the quarter.&nbsp;The double beat is a welcome relief after the company missed top-line expectations in the second quarter.Dexcom announced a management transition as Teri Lawver, who serves as chief commercial officer, is set to retire by the year-end. Sayer will assume her responsibilities as the company begins a search for a replacement.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dexcom-stock-plunges-despite-q3-beat-but-retail-sentiment-improves/cJ2lHI0R7u">Dexcom Stock Plunges Despite Q3 Beat But Retail Sentiment Improves</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Dexcom and WisdomTree has cheered retailers with their earnings reports, and Lyell with an M&A transaction.

Earnings news and an M&A deal have improved retail sentiment toward these 3 stocks in Friday's premarket.

Dexcom Inc

WisdomTree Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.04
Prev Close	$11.31
Open	$11.26
Dividend Yield	0.00%
50-Day Moving Average	$11.02
Beta	1.61
Avg. Volume	137,861.96
PE Ratio	-0.94

52-Week High	$45.00
52-Week Low	$7.20
Market Capitalization	$270.54M
EPS (Annual)	-$16.06
Price to Book	1.10
Revenue Per Employee	$223.60

Feed

News

Sentiment

Earnings

Fundamentals

Info

LYEL Fundamentals